| Literature DB >> 33171773 |
Laísa de P Fernandes1, Júlia M B Silva2, Daniel O S Martins2, Mariana B Santiago2, Carlos H G Martins2, Ana C G Jardim2, Guedmiller S Oliveira1, Marcos Pivatto1, Rafael A C Souza1, Eduardo de F Franca3, Victor M Deflon4, Antonio E H Machado5,6, Carolina G Oliveira1.
Abstract
Considering our previous findings on the remarkable activity exhibited byEntities:
Keywords: biological application; cobalt(III) complexes; mass spectrometry; molecular docking
Year: 2020 PMID: 33171773 PMCID: PMC7664407 DOI: 10.3390/ijms21218355
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Scheme 1Synthesis of the cobalt(III) complexes.
Figure 1Electrospray ionization (ESI) mass spectra of cobalt(III) complexes 1 and 2. (A) (+)-high-resolution electrospray ionization mass spectra (HRESIMS) spectrum of 1, m/z 473.0734 [M]+ (calcd. for C18H22CoN8S2, 473.0735, Δ –0.21 ppm); (B) (+)-HRESIMS spectrum of 2, m/z 597.1049 [M]+ (calcd. for C28H26CoN8S2, 597.1048, Δ 0.17 ppm); (C) ESI–MS/MS spectrum of the molecular ion m/z 473.0733; and (D) ESI–MS/MS spectrum of the molecular ion m/z 597.1053.
Figure 2Fragmentation pathway proposed for 1 (m/z 473) and 2 (m/z 597) analyzed by (+)-ESI–MS/MS.
Minimum inhibitory concentration (MIC, µg/mL) and minimum bactericidal concentration (MBC, µg/mL) in µg/mL against buccal bacteria strains.
| Bacterial Strains | Hatc-Me | Hatc-Ph | [Co(atc-Me)2]+ | [Co(atc-Ph)2]+ | CoCl2·6H2O | CHD * | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | |
| 12.5 | 12.5 | 100 | 100 | 400 | 400 | 0.78 | 0.78 | 100 | 100 | 0.46 | 0.46 | |
| 12.5 | 12.5 | 100 | 100 | 400 | 400 | 1.56 | 1.56 | 100 | 100 | 1.84 | 1.84 | |
| 6.25 | 6.25 | 100 | 100 | 400 | 400 | 0.39 | 0.39 | 100 | 100 | 0.92 | 0.92 | |
| 25 | 25 | 400 | 400 | 400 | 400 | 12.5 | 25 | >400 | >400 | 0.46 | 0.46 | |
| 50 | 50 | 400 | 400 | 400 | 400 | 0.78 | 0.78 | >400 | >400 | 0.92 | 0.92 | |
| 25 | 25 | 100 | 100 | 400 | 400 | 3.12 | 3.12 | 100 | 100 | 0.92 | 0.92 | |
| >400 | >400 | >400 | >400 | 400 | 400 | 6.25 | 6.25 | >400 | >400 | 3.68 | 3.68 | |
* CHD: Chlorhexidine, positive control.
Figure 3Time–kill curve profiles for complex 2 for caries bacteria as an antibacterial agent in different concentrations of MBC results, (A) E. faecalis; (B) S. salivarius; (C) S. sanguinis; (D) S. mitis; (E) S. mutans; (F) L. paracasei.
Figure 4Activity of compounds on chikungunya virus (CHIKV) infection and viability of baby hamster kidney (BHK) 21 cells. BHK 21 cells were infected with CHIKV nanoluc and simultaneously treated with the compound. After 16 h post-infection (p.i.), cells were lysed, and a Renilla luciferase assay was performed to assess CHIKV replication rates. In parallel, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was performed. Mean values of a minimum of three independent experiments each measured in triplicate are represented. **** p < 0.001/* p < 0.05 were considered significant.
Figure 5Interaction network between the [Co(atc-Ph)2]+ complex and (A) S. mutans; (B) S. mitis; (C) S. sanguinis; and (D) L. paracasei protein structures. For clarity, the non-polar hydrogen atoms of the metal complex are omitted.